Anixa Biosciences (ANIX) Net Equity Issued and Repurchased (2013 - 2025)
Anixa Biosciences' (ANIX) quarterly Net Equity Issued and Repurchased came in at $454000.0 in Q4 2025, up 1665.52% YoY from $25714.8 in Q4 2024, and down 76.44% on a QoQ basis from $1.9 million in Q3 2025.
Anixa Biosciences (ANIX) Net Equity Issued and Repurchased (2013 - 2025) Analysis & Trends
Anixa Biosciences (ANIX) has 8 years of Net Equity Issued and Repurchased data on file, last reported at $454000.0 in Q4 2025.
- Quarterly Net Equity Issued and Repurchased rose 1665.52% year-over-year to $454000.0 in Q4 2025, while the trailing twelve-month figure through Oct 2025 was $2.4 million (down 19.53% YoY) and the FY2025 annual result came in at $2.4 million, down 19.53% from the prior year.
- Net Equity Issued and Repurchased fell to $454000.0 in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $6.0 million in Q1 2021 to a low of -$341000.0 in Q4 2021.
- A 3-year average of $1.5 million and a median of $454000.0 in 2025 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased slumped 131.4% — and 2025, when it soared 4382.22%.
- Tracing ANIX's Net Equity Issued and Repurchased over 3 years: stood at -$341000.0 in 2021, then soared by 91.5% to -$29000.0 in 2024, then soared by 1665.52% to $454000.0 in 2025.
- The last three Net Equity Issued and Repurchased figures came in at $454000.0 (Q4 2025), $1.9 million (Q3 2025), and $14000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2025 | 454,000.00 |
| Oct 31, 2025 | 454,000.00 |
| Jul 31, 2025 | 1.93 Mn |
| Jul 31, 2025 | 1.93 Mn |
| Apr 30, 2025 | 14,000.00 |
| Apr 30, 2025 | 14,000.00 |
| Jan 31, 2025 | -17,000.00 |
| Jan 31, 2025 | -17,000.00 |
| Oct 31, 2024 | -29,000.00 |
| Oct 31, 2024 | -29,000.00 |
| Jul 31, 2024 | -45,000.00 |
| Jul 31, 2024 | -45,000.00 |
| Apr 30, 2024 | 833,000.00 |
| Apr 30, 2024 | 833,000.00 |
| Jan 31, 2024 | 2.20 Mn |
| Jan 31, 2024 | 2.20 Mn |
| Oct 31, 2021 | -341,000.00 |
| Oct 31, 2021 | -341,000.00 |
| Apr 30, 2021 | 5.22 Mn |
| Apr 30, 2021 | 5.22 Mn |